• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Das Avanindra

    12/20/24 6:53:50 PM ET
    $TDAC
    Get the next $TDAC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Das Avanindra

    (Last) (First) (Middle)
    C/O TRANSLATIONAL DEVELOPMENT ACQ CORP.
    52 E. 83RD STREET

    (Street)
    NEW YORK NY 10028

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/20/2024
    3. Issuer Name and Ticker or Trading Symbol
    Translational Development Acquisition Corp. [ TDAC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Ordinary Shares (1) (1) Class A Ordinary Shares 4,657,500(2) (1) I See Footnote(3)
    Explanation of Responses:
    1. As described in the issuer's registration statement on Form S-1 (File No. 333-282763) under the heading "Description of Securities - Ordinary Shares, "the Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation issuer's initial business combination, on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and has no expiration date.
    2. Includes up to 607,500 shares subject to forfeiture by TDAC Partners LLC (the "Sponsor") depending on the extent to which the underwriters' option to purchase additional units is exercised.
    3. The Reporting Person is a managing member of the Sponsor and as a result may be deemed to beneficially own the securities held of record by the Sponsor. The Reporting Person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
    /s/ Avanindra C. Das 12/20/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TDAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TDAC

    DatePrice TargetRatingAnalyst
    9/21/2021$16.00Outperform
    Northland Capital Markets
    More analyst ratings

    $TDAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

    NEW YORK, July 6, 2026 /PRNewswire/ -- Translational Development Acquisition Company (NYSE:TDAC) ( "TDAC") announced that ProLogium has filed their initial F-4 with the SEC driving the companies forward towards a successful execution of the de-SPAC transaction. This filing gives the SEC and investors at large a fuller view into the history of ProLogium and further supporting information into the merger transaction that was announced on May 27, 2026. Michael Hoffman, Chairman and CEO of TDAC, commented, "We continue to be tremendously excited to work with the ProLogium team on this transaction. We believe that this F-4 filing with the SEC will provide investors significant color into the comp

    7/6/26 9:51:00 AM ET
    $TDAC

    TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote

    85% of Shares are not Redeemed, resulting in TDAC maintaining $156.8mm in trust95% of the Shares Voted Were In Favor of the ExtensionThese Great Results Follow the Momentum of the May 27, 2026 announcement of TDAC's Entry into a Merger Agreement with PrologiumPrologium is a global leader in next generation lithium ceramic battery technology, moving into growth markets, including AI Data Centers, aerospace, robotics, defense and electric vehiclesNEW YORK, June 22, 2026 /PRNewswire/ -- Translational Development Acquisition Company (NYSE:TDAC) (the "Company" or "TDAC") announced the very successful results of the shareholder vote held on 6/17/26 regarding the proposed extension of the SPAC life

    6/22/26 7:05:00 AM ET
    $TDAC

    ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.

    ProLogium reached commercial-scale manufacturing for solid-state batteries in 2013, later delivered the world's first solid-state battery demo car with ENOVATE Motor in 2019. ProLogium has shipped a total of over 2.4 million battery cells to customers since 2013, of which more than 800,000 are its 3rd-generation batteries from the Gigafactory in Taiwan. With a portfolio of 1,100+ patents, ProLogium has introduced its 4th-generation superfluidized inorganic solid-state battery solution with zero thermal runaway, high energy density, low temperature performance, fast charging, competitive cost, and commercial readiness. Pre-money valuation of ProLogium is expected to be approximately $3.8 bill

    5/27/26 7:00:00 AM ET
    $TDAC

    $TDAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Trident Acquisitions with a new price target

    Northland Capital Markets initiated coverage of Trident Acquisitions with a rating of Outperform and set a new price target of $16.00

    9/21/21 8:09:12 AM ET
    $TDAC

    $TDAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman and CEO Hoffman Michael B

    4 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    5/29/26 4:05:16 PM ET
    $TDAC

    SEC Form 3 filed by new insider Jarratt Christopher Kenneth

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    1/6/25 4:05:09 PM ET
    $TDAC

    SEC Form 3 filed by new insider Keith Curtis T

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    12/20/24 6:59:32 PM ET
    $TDAC

    $TDAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.

    SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)

    7/16/26 1:38:54 PM ET
    $TDAC

    Translational Development Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Translational Development Acquisition Corp. (0001926599) (Filer)

    7/8/26 8:05:31 AM ET
    $TDAC

    SEC Form DEFA14A filed by Translational Development Acquisition Corp.

    DEFA14A - Translational Development Acquisition Corp. (0001926599) (Filer)

    6/23/26 10:25:11 AM ET
    $TDAC

    $TDAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - Trident Acquisitions Corp. (0001673481) (Subject)

    2/12/21 4:30:21 PM ET
    $TDAC